93 Views | 39 Downloads
Christina A. Rostad, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA USA. Email:christina.rostad@emory.edu
We thank Dr. Jens Wrammert for kindly sharing purified RBD protein antigen. We thank clinical research coordinators Felicia Glover, Vikash Patel, Amber Samuel, and clinical research nurses Lisa Macoy and Kathy Stephens for their assistance enrolling patients and collecting specimens. We thank Theda Gibson, Wensheng Li, and the Emory Children’s Center Vaccine Research Clinic (ECC-VRC) laboratory for their assistance processing specimens. We thank the Children’s Healthcare of Atlanta research laboratory for their assistance in collecting residual specimens. We also thank the study participants and their families for generously donating their time and blood to further our understanding of COVID-19 and MIS-C.
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Evan J. Anderson reports a relationship with AbbVie Inc that includes: consulting or advisory. Evan J. Anderson reports a relationship with Medscape LLC that includes: consulting or advisory. Evan J. Anderson reports a relationship with Pfizer Inc that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Sanofi Pasteur Inc that includes: board membership, consulting or advisory, and funding grants. Evan J. Anderson reports a relationship with AstraZeneca Medimmune that includes: funding grants. Evan J. Anderson reports a relationship with Regeneron Pharmaceuticals Inc that includes: funding grants. Evan J. Anderson reports a relationship with PaxVax that includes: funding grants. Evan J. Anderson reports a relationship with GlaxoSmithKline USA that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Merck & Co Inc that includes: funding grants. Evan J. Anderson reports a relationship with Novavax Inc that includes: funding grants. Evan J. Anderson reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Micron Biomedical that includes: funding grants. Evan J. Anderson reports a relationship with Kentucky BioProcessing Inc that includes: board membership. Christina A. Rostad reports a relationship with Biofire Diagnostics Inc that includes: funding grants. Christina A. Rostad reports a relationship with GlaxoSmithKline USA that includes: funding grants. Christina A. Rostad reports a relationship with AstraZeneca Medimmune that includes: funding grants. Christina A. Rostad reports a relationship with Micron Biomedical that includes: funding grants. Christina A. Rostad reports a relationship with Novavax Inc that includes: funding grants. Christina A. Rostad reports a relationship with Merck & Co Inc that includes:. Christina A. Rostad reports a relationship with PaxVax that includes: funding grants. Christina A. Rostad reports a relationship with Pfizer Inc that includes: funding grants. Christina A. Rostad reports a relationship with Regeneron Pharmaceuticals Inc that includes: funding grants. Christina A. Rostad reports a relationship with Sanofi Pasteur Inc that includes: funding grants. Evan J. Anderson reports a relationship with WIRB-Copernicus Group Inc that includes: board membership. Evan J. Anderson reports a relationship with ACI Clinical that includes: board membership. Christina A. Rostad has patent Chimeric RSV, Immunogenic Compositions, and Methods of Use. with royalties paid to Meissa Vaccines, Inc.
E.J.A. has consulted for Pfizer, Sanofi Pasteur, Janssen, GSK, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanonfi-Pasteur, Janssen, and Micron. He also serves on data and safety monitoring boards for Kentucky BioProcessing, Inc., and Sanofi-Pasteur. He serves on a data adjudication board for WCG and ACI Clinical. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. C.A.R.’s institution has received funding to conduct clinical research unrelated to this manuscript from BioFire Inc., GSK, MedImmune, Micron, Merck, Novavax, PaxVax, Regeneron, Pfizer, and Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. Her institution has received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines.
This work was funded by Emory University and Children’s Healthcare of Atlanta, and by the U.S. Centers for Disease Control and Prevention.
© 2023 The Authors